Status:
COMPLETED
AZD1152 in Patients With Advanced Solid Malignancies
Lead Sponsor:
AstraZeneca
Conditions:
Tumors
Eligibility:
All Genders
18-130 years
Phase:
PHASE1
Brief Summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days ...
Eligibility Criteria
Inclusion
- Histological or cytological confirmation of a solid, malignant tumour
- At least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Exclusion
- Participation in an investigational drug study within the 21 days prior to therapy or those who have not recovered from the effects of an investigational study drug
- Recent major surgery within 4 weeks prior to entry into the study
Key Trial Info
Start Date :
May 23 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00338182
Start Date
May 23 2006
End Date
March 1 2017
Last Update
April 24 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Boston, Massachusetts, United States
2
Research Site
New York, New York, United States